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Abstract
In this paper we use a simple model to explore the function of the gene Osteosarcoma-9. We
are in particular interested in understanding the role of this gene as a potent anti-apoptotic factor.
The theoretical description is constrained by experimental data from induction of apoptosis in cells
where OS-9 is overexpressed. The data available suggest that OS-9 promotes cell viability and confers
resistance to apoptosis, potentially implicating OS-9 in the survival of cancer cells. Three different
apoptosis-inducing mechanisms were tested and are here modeled. A more complex and realistic model
is also discussed.
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I. INTRODUCTION
Of the various Expressed Sequence Tags of unknown function which appear to be regulated
when apoptosis is initiated [1], one was identified as the gene Osteosarcoma-9 (OS-9 GI:580310),
which is mapped to the chromosomal region 12q13-q15. This region is amplified in various
human cancers, including sarcomas and osteosarcomas. The observation that none of the
known genes in this region is amplified in all tested tumors suggests that other genes must exist
that are commonly amplified in different cancer types. The functional analysis of the OS-9 gene
is thus of interest for its potential anti-apoptotic role in the development of cancer.
However, little functional data exist for OS-9. The identified sequence homology of OS-
9 to both nucleolin and protein tyrosine phosphatase 1B (PTP-1B) was found to entail no
functional similarities [2]. Being driven from a TATA-less promoter [3], however, suggests that
OS-9 may be involved in cell-cycle regulated housekeeping or cell viability [2]. More recently, it
was reported that OS-9 promotes oxygen-dependent degradation of hypoxia inducible factor 1α
(HIF-1α) via binding to both HIF-1α and the HIF prolyl hydroxylases [4]. This is a surprising
result since overexpression of HIF-1α is characteristic of most human cancer and inhibition
of HIF-1 impairs tumor growth. A role for OS-9 in the control of tumor progression as a
tumor-suppressor gene has also been advanced [5].
In Ref. [6] the first observational data set on a preliminary functional analysis of the product
of the OS-9 gene was presented. The authors used overexpression of OS-9 isoform 2 cDNA
in two murine FDC-P1 cell line populations, namely FDB-P1-17V (17V) and FDB-P1-17VIII
(17VIII), and siRNA depletion of OS-9 specific mRNA in human umbilical vein endothelial cells
(HUVEC) to study the role of OS-9 in induction of apoptosis by three mechanisms: interleukin
3 (IL-3) deprivation of IL-3-dependent murine myeloid cells [7], staurosporine treatment [8, 9]
and tumor necrosis factor α (TNFα) treatment [10]. The data on the number of viable and
apoptotic cells in the two OS-9-overexpressed cell line populations were obtained from trypan
blue exclusion analysis and from fluoresence-activated cell sorter (FACS) analysis after treat-
ment with Annexin V and propidium iodide (PI). From the comparison with the cell population
having the vector confering the Haemagglutinin (HA) gene only (negative control), the data
suggest the following results: 1) promotion of cell viability upon induction of apoptosis by
withdrawal of IL-3; 2) promotion of cell resistance to apoptosis upon induction of apoptosis by
addition of staurosporine and TNFα; 3) concentration dependence of resistance to apoptosis by
addition of staurosporine; 4) resistance to apoptosis, with HUVEC’S precipitating to apoptosis
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upon blockage of the OS-9 function; 5) no effect on cell proliferation of any of the mechanisms.
This paper proposes a mechanistic model for the OS-9 functional data presented in Ref. [6],
thus giving theoretical support to the interpretation of the experimental results by E. Vour-
vouhaki et al. The model is general enough to avoid speculations about the particular dynamics
associated with OS-9, but informative to the point of showing, in a quantitative manner, the
impact of OS-9 in cell fate. In particular, such a model must reproduce induction of apopto-
sis upon treatment with an apoptotic agent or upon withdrawal of a vital agent, and explain
resistance to apoptosis and cell viability as a consequence of OS-9 overexpression.
This paper is organized as follows. In section II we introduce the minimal model for the
kinetics of a population of murine FDC-P1 cells with OS-9 overexpressed when subject to
three different mechanisms for induction of apoptosis, namely withdrawal of IL-3, addition
of staurosporine and addition of TNFα. We analyse the biological system as a sequence of
biochemical interactions which we then formulate into a mechanistic model encompassed by a
system of kinetical equations. In section III we optimize the parameters which describe the
experimental results by fitting to the data the kinetical equations. For the optimal values for
the parameters, the kinetical equations are expected to model the biological system within the
observational errors and the limitations of a theoretical construct, as discussed in section IV.
II. MODEL FOR OS-9 OVEREXPRESSION IN APOPTOSIS INDUCTION
In this section we analyse the biological system described by the experimental data in Ref. [6]
as a sequence of biochemical interactions modeled by the overexpression of the OS-9 protein
in two cell line populations of murine FDC-P1 cells, namely 17V and 17VIII. The level of
OS-9 mRNA in 17VIII was confirmed by Real Time Polymerase Chain Reaction (PCR) to
be approximately four times that of 17V [6]. Given the lack of knowledge on how the OS-9
protein acts in the cell, the entailed biochemical interactions are reduced to the simplest sensible
functional form. In the biological system, we identify two competing effects, namely induction
of apoptosis on the one hand, and on the other hand promotion of cell viability and resistance
to apoptosis due to OS-9 overexpression.
Apoptosis is induced by the addition of an apoptotic agent, identified as aa, or by the
withdrawal of a vital agent to the survival of the cells, identified as va. Here we describe
induction of apoptosis by a decay rate of viable cells in the presence of an apoptotic agent or
absence of a vital agent. These rate parameters are characteristic of the apoptotic mechanism
3
and hence assumed to be dependent on the specific agent.
The cell response to apoptosis induction will depend on the induction mechanism. Thus,
addition of an apoptotic agent will provoke the cell to resist apoptosis, in which case we will
be assessing the OS-9 action in resistance to apoptosis. Conversely, withdrawal of a vital agent
will challenge the cell to strive for survival, in which case we will be assessing the action of
OS-9 in promoting cell viability.
These are the basic biochemical interactions which, together with the normal viable cell
growth, must be contemplated by any model that attempts to describe the biological system
being considered. We now proceed to formulate the simplest possible kinetical model containing
just as many parameters as the data readily available allow us to constrain. An extension of such
model for an arbitrary number of possible intermediary mechanical interceptions is presented
as an illustration of the increased level of data required to constrain an increased level of
interaction.
A. Kinetical Model
In our first attempt to model the OS9 role, we collapse the biochemical interactions into
a minimal set of kinetical equations. This first-order approximation avoids speculation and
allows us to concentrate on the effects of OS-9 overexpression on promotion of viability and
resistance to apoptosis. In the simplest plausible model, we have three variables: viable cells
cv, apoptotic cells ca and dead cells cn. The evolution in time of the number of cells in each
of these cell stages is dependent on the reaction of the cell population to the absence of vital
agent va or on the interaction with the apoptotic agent aa, and on the subsequent cell response
derived from an OS-9 overexpression.
The biochemical interactions can be analysed in fundamental phenomenological processes
which we represent schematically by the following system of kinetical equations:
cv
λ
−→ 2cv, (1)
cv
α(1−β)
−→ ca, (2)
ca
γ(1−δ)
−→ cn. (3)
Here Eqn. (1) corresponds to cell proliferation, Eqn. (2) to apoptosis induction by either addition
of an apoptotic agent or withdrawal of a vital agent and Eqn. (3) to cell death. The reactions
will now be described in detail.
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Viable cells grow at a rate λ. The absence of any effect of the OS-9 overexpression on cell
proliferation, as concluded from the DNA content analysis, implies that λ = constant. The
effective cell growth, however, depends on the ratio of the number of viable cells to the carrying
capacity cv(max). As a first approximation, we assume that the cells proliferate effectively at a
rate λ(1−cv/cv(max)). The choice of the linear functional form for the effective cell proliferation
rate on the carrying capacity was motivated by the treatment of various aspects of cancer
modeling discussed in References [11, 12].
Equation (2) describes the transition from viable cells to apoptotic cells induced by either
addition of an apoptotic agent aa or removal of a vital agent va. For both apoptosis induction
processes we use the same expression for the conversion rate: α(1 − β). The two parameters
involved are used to segregate the effect of OS-9 overexpression. The parameter β is a function of
the OS-9 overexpresssion, β = β([OS-9]), and takes values in the interval [0, 1]. The parameter
α absorbs all other contributions to the conversion rate and depends on the specific agent
leading to apoptosis. All experimental situations described in this paper use either one of these
two induction processes; no experiment uses both. Although both apoptosis-inducing processes
have the same rate expression, the interpretation given to the parameter β is different. In the
case of vital agent withdrawal, the β parameter of Eqn. (2) measures promotion of cell viability
modulated by the OS-9 overexpression. However, in the case of apoptotic agent addition, β
reflects resistance of a viable cell to becoming apoptotic. This process must thus take place
upstream in the apoptotic signal pathway before the activation of the initiator caspases (caspase-
8, -9 and -12) [13].
Cell death, as expressed in Eqn. (3), progresses at a rate given by the expression γ(1 − δ).
As done previously, this expression segregates the dependence on OS-9 overexpression. The
parameter δ is a function of the OS-9 overexpression, δ = δ([OS-9]), and takes values in the
interval [0, 1]. Apoptotic cells will enter the final stage of apoptosis at a rate γ. Correspondingly,
the parameter δ reflects resistance of an apoptotic cell to entering such stage characterized
by the cell turning into an apoptotic body and eventually dying. This effect will take place
downstream in the apoptotic signal pathway before the activation of the executioner caspases
(caspase-3, -6 and -7) [13].
It is important to emphasise the modulation produced by OS-9 overexpression in these
reactions. This modulation is encapsulated in the parameters β = β([OS-9]) and δ = δ([OS-9]),
which are such that β, δ ∈ [0, 1], where 0 denotes the control (normal) expression and all other
values reflect a contribution of OS-9 overexpression.
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We now proceed to formulate the phenomenological model into a system of differential
equations for the three variables. In the case of induced apoptosis by the addition of one
apoptotic agent, the interaction can be broken down as follows: a) binding of aa to cv; b)
interception by the OS-9-codified protein of a signal pathway triggered from an effective binding;
c) blocking of apoptosis induction in cv or blocking of necrosis induction in ca, depending on
the position in the signal pathway of the interception; d) survival or death of ca.
For a contact rate α, α molecules of the apoptotic agent will bind to a cell per unit time.
If we assume that from each contact point a signal for apoptosis is always started, then αcv
will be the number of triggered apoptotic signals per unit time. Before starting the upstream
apoptosis-inducing caspase chain reaction, β(αcv) apoptotic signals interact with a molecule of
the OS-9-codified protein per unit time, resulting in the interruption of the signal pathway. The
remaining (1 − β)(αcv) signals will successfully induce apoptosis. In cells where apoptosis has
already been triggered, and in the absence of OS-9 overexpression, the final stage of apoptosis is
reached at a rate γca. In the presence of OS-9 overexpression, however, for δ(γca) successful OS-
9-led interruption of a downstream signal for necrosis, the final stage of apoptosis will instead
be reached at γca(1− δ). Combining the reactions described above, we find that the variation
in time of the number of viable cells is given by
dcv
dt
= λcv
(
1−
cv
cv(max)
)
− αcv(1− β). (4)
Given the time scale of the experiment, cell decay is rendered negligible and thus unaccounted
for. This is supported by the data recorded in the FACS diagrams in Ref. [6], which suggest that
necrosis is sourced by apoptosis rather than by decay. It follows that the number of apoptotic
cells will vary in time as
dca
dt
= αcv(1− β)− γca(1− δ), (5)
and the number of dead cells as
dcn
dt
= γca(1− δ). (6)
This is an example of a quasispecies-type system [11].
In the case of induced apoptosis by withdrawal of a vital agent, the interaction can be broken
down in a similar way to the previous case, with the apoptosis signal now being driven through
the mitochondria/cytochrome c pathway [7]. The induction of apoptosis can still be described
by a decay mechanism of rate αcv. This means that α apoptoptic signals are triggered per unit
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time in a cell subject to a vital agent-depleted medium. Of the total αcv apoptotic signals
generated, β(αcv) are intercepted by the OS-9 protein, which measures the rate of failure of
apoptosis induction.
Both mechanisms discussed here are independent and each comprises either addition of an
apoptotic agent or withdrawal of a vital agent. Consequently, we would expect that each
highlights an independent function of OS-9, respectively promotion of viability or resistance to
apoptosis.
B. Chemical Model
The model described in the previous subsection can be regarded as a black box model which
acts on a given initial state to reproduce the observed final state in a OS-9-dependent way. If
the detailed modus operandus of the OS-9 action in the cell was known, then the system would
be approximated by a multiple little black box model, with smaller black boxes describing inter-
mediate reactions triggered by intermediary apoptotic agents and constrained by intermediary
initial and final known states. For one intermediary apoptotic agent, a(1)a , in the upstream
pathway between the trigger of the exterior apoptotic agent on the membrane of the cell and
the interception by the OS-9 protein which binds to the signal at the rate αup(1), the variation
in time of the number of viable cells will be given by
dcv
dt
= λcv
(
1−
cv
cv(max)
)
− αcv
[
αup(1) − βαup(1) −
(
1− αup(1)
)]
= λcv
(
1−
cv
cv(max)
)
− αcv
[
αup(1) (2− β)− 1
]
; (7)
for two intermediary upstream apoptotic agents, a(1)a and a
(2)
a , with binding rates αup(1) and
αup(2) respectively, we have that
dcv
dt
= λcv
(
1−
cv
cv(max)
)
− αcvαup(1)αup(2)
+ αcv
[
βαup(1)αup(2) + αup(1)
(
1− αup(2)
)
+
(
1− αup(1)
)]
= λcv
(
1−
cv
cv(max)
)
− αcv
[
αup(1)αup(2) (2− β)− 1
]
; (8)
and similarly for n intermediary chemical agents upstream in the apoptic pathway
dcv
dt
= λcv
(
1−
cv
cv(max)
)
− αaacv
[
(2− β)
n∏
i=1
αup(i) − 1
]
. (9)
To account for the OS-9-modulated interception of the downstream signal pathway we must
allow for intermediary downstream necrotic agents, n(n)a , binding to the OS-9 protein at rates
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αdown(n). It follows that
dca
dt
= αaacv
[
(2− β)
n∏
i=1
αup(i) − 1
]
− γca
[
(2− δ)
n∏
i=1
αdown(i) − 1
]
. (10)
The role of each of these agents in the transmission of the apoptotic signal must be known and
included in the dynamical system. To study the potential role of such a weakly known gene such
as the OS-9, this model is therefore inadequate. As the logical extension of the kinetical model
to a series of such smaller systems, this model could be applied to a multiple level interaction
approach to biological systems with available multiple level data constraints [14]. It might also
provide further insight into some unexpected results obtained with the kinetical model. We
hope to pursue this in the future.
III. EXPERIMENTAL AND THEORETICAL RESULTS
In this section we proceed to use the system of first-order, coupled differential equations
derived in the previous section to model the data reported in Ref. [6]. This system is used
to model the two different apoptotic inducing mechanisms, namely addition of an apoptotic
agent or withdrawal of a vital agent. In this paper we shall only use what we called the kinetic
model. We want to solve for the time evolution of the number of viable cells cv(t) and of
apoptotic cells ca(t) using the data in Ref. [6] to constrain the parameters α, β, γ and δ of the
differential equations. In particular we are interested in the values for the parameters β and δ
which measure the contribution of the OS-9 overexpression in the system.
The data consist of the average of nine readings of the number of viable cells and the number
of apoptotic cells obtained from trypan blue exclusion analysis and from FACS analysis after
treatment with Annexin V and PI, all experiments having been performed three times and
each in triplicate. The FACS analysis sorts cells that are 1) alive, 2) undergoing apoptosis,
3) undergoing necrosis and that are 4) in between apoptosis and necrosis, thus allowing to
discriminate alive, apoptotic and dead cells. The trypan blue exclusion analysis simply separates
dead from alive cells, lacking the sophistication and sensitivity to discriminate viable cells from
apoptotic cells. In a modeling study that considers all three of the cell stages, the data from
the typan blue exclusion analysis are inappropriate for use and hence will not be included here.
The solutions were determined numerically with mathematica (Wolfram Research). For
the parameter estimation we implemented a sampling algorithm which calculates a cost function
of a list of values for each parameter that we want to estimate. The cost function is defined as the
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sum of the square of differences between the experimental points and the corresponding points
of the solution to the kinetical system. The minimum of the cost function line, or surface, defines
the parameter value which optimally fits the experimental data. The precision of the method
is defined by the density of points in the search space. The optimal values thus determined
for all the parameters were then used to plot the solutions for cv(t) and ca(t) which we present
in this paper. We applied the algorithm to both the average values and the corresponding
maxima and minima encompassed by the error bars. For each data set, we obtained from
three to eight estimates for (and depending on) each parameter by fitting the equations to the
average and to the extreme data points. The parameters obtained from the average data points
were combined to produce the induced average solution (represented by a continuous line); the
parameters obtained from the extreme data points were combined to produce the maximum
and minimum solutions (represented by dashed lines siding the continuous line), which reflect
the propagation of the measurement errors and thus define the induced error interval of all
possible curves capable of optimally fitting the data within the experimental errors. All the
curves show percentages normalized to the initial number of viable cells, cv(t = 0) = 1× 10
5.
From the experimental curves we can extrapolate the values for λ and cv(max) adjusted to
the system. Here we use λ = 0.01 and cv(max) = 20 × 10
5. From the data on the HA-only
marked (negative control) population we estimate the parameters which do not depend on the
OS-9 overexpression, namely α and γ. We proceed to apply them to the OS-9-overexpressed
cell line populations to estimate the parameters which measure the overexpression of OS-9,
namely β and δ. The data analysis of each apoptosis-inducing mechanism is introduced by the
interpretation advanced in Ref. [6] based on a qualitative reading of the experimental results,
which we then confront with the interpretation of the quantified, data-constrained parameters
of the model.
A. Withdrawal of IL-3 in FDC-P1 cells
Here we analyse apoptosis induction by IL-3 deprivation of IL-3-dependent cells. The cor-
responding apoptotic mechanism is that of withdrawal of a vital agent and is described by the
system of equations (4–6), with β having the interpretation of OS-9 overexpression modulation
in cell viability. The experimental results are collected in Figs. 2B and 2C of Ref. [6], which we
reproduce in Figs. 1(a) and 2(a) respectively.
First we solve for cv(t) given by Eqn. (4) and fit it to the number of viable cells shown in
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Fig. 1(a). In the absence of OS-9 overexpression this equation has only one free parameter,
namely α. Setting β = 0, we fit the solution to the curve for the number of viable cells in the
HA-only marked cell population to find α = 0.057+0.001
−0.001. In the presence of OS-9 overexpression
we have additionally the parameter β to consider. We now use the results found for α to
fit cv(t) to the experimental curve for the number of viable cells in the OS-9-overexpressed
cell line populations and thus to find the corresponding β. We obtain β17V = 0.17
+0.04
−0.05 and
β17V III = 0.31
+0.03
−0.04 for the 17V and the 17VIII cell line populations respectively. The resulting
plots are depicted in Fig. 1(b).
We then solve for ca(t) given by Eqn. (5) and fit it to the number of apoptotic cells shown in
Fig. 2(a) to determine the parameters γ and δ. Using α = 0.057+0.001
−0.001 and setting β, δ = 0, the
fitting of the solution to the number of apoptotic cells in the negative control population gives
γ = 0.30+0.04
−0.04. Substituting now also for β the results β17V = 0.17
+0.04
−0.05 and β17V III = 0.31
+0.03
−0.04,
the fitting of the solution to the number of apoptotic cells in the OS-9-overexpressed cell line
populations gives δ17V = 0.099
+0.16
−0.099 and δ17V III = 0.086
+0.14
−0.086 respectively. The resulting plots
are depicted in Fig. 2(b).
In accordance with the experimental data, our mathematical model returns no significant
difference between the number of apoptotic cells in the negative control population and that in
the OS-9-overexpressed cell line populations, as illustrated by the shared pattern of the curves.
We note that it captures rather closely the crossing point where the number of apoptotic cells
in the OS-9-overexpressed cell populations is the same and the starting dominance of the 17V
population over the 17VIII population is reversed. As anticipated by E. Vourvouhaki et al. [6],
this case illustrates promotion of cell viability (as shown by β 6= 0) and possibly downstream
resistance to apoptosis (as shown by δ 6= 0). Our mathematical model allows to separate
the effect of promotion of viability, as encapsulated in a non-vanishing β, from the effect of
downstream resistance to apoptosis, as encapsulated in a non-vanishing δ.
B. Staurosporine treatment in FDC-P1 cells
Here we analyse apoptosis induction by treatment with staurosporine. The apoptotic mech-
anism is that of addition of an apoptotic agent and is described by the system of equations
(4–6), with β having the interpretation of OS-9 overexpression modulation in apoptosis resis-
tance. The experimental results are collected in Figs. 5B and 5C of Ref. [6].
Two different concentrations of staurosporine were considered: 1µM and 0.1µM. The
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data for [staurosporine]=1µM are reproduced in Figs. 3(a) and 4(a); the data for
[staurosporine]=0.1µM are reproduced in Figs. 5(a) and 6(a). We do not impose any addi-
tional constrain in the system to account for the concentration change. In other words, we let
the parameters α and β absorb the changes induced by the different concentrations.
1. [Staurosporine]=1µM
First we solve for cv(t) for [staurosporine]=1µM, given by Eqn. (4), and fit it to Fig. 3(a)
to find α = 0.20+0.005
−0.01 from cv in the negative control population, and β17V = 0.18
+0.005
−0.05 and
β17V III = 0.24
+0.03
−0.07 from the corresponding OS-9-overexpressed cell line populations. The results
are plotted in Fig. 3(b).
We then solve for ca(t) for [staurosporine]=1µM, as given by Eqn. (5), and fit it to Fig. 4(a)
in order to determine the parameters γ and δ. Setting β, δ = 0 and using α = 0.20+0.005
−0.01 , we fit
the solution to the experimental curve for the number of apoptotic cells in the negative control
population and obtain γ = 0.72+0.18
−0.10. We proceed to fit the solution to the experimental number
of apoptotic cells in the OS-9-overexpressed cell line populations, using the values determined
above for the other parameters, to find that δ17V = 0.19
+0.17
−0.16 and δ17V III = 0.27
+0.16
−0.13. The results
are plotted in Fig. 4(b).
2. [Staurosporine]=0.1µM
First we solve for cv(t), given by Eqn. (4), and fit the solution to the curves for cv depicted
in Fig. 5(a). Setting β = 0, we fit the solution to the experimental curve for cv in the negative
control population and find α = 0.15+0.01
−0.005. Fitting the solution to the experimental curves for
cv in the OS-9-overexpressed cell line populations with α = 0.15
+0.01
−0.005 we find β17V = 0.19
+0.06
−0.05
and β17V III = 0.35
+0.05
−0.06.
We then proceed to solve for ca(t), given by Eqn. (5), and fit the solution to the experimental
curves for ca depicted in Fig. 6(a). Setting β, δ = 0 and α = 0.15
+0.01
−0.005, we fit the solution to
the experimental curve for ca in the negative control population and find γ = 0.20
+0.005
−0.01 . This
value is substantially lower than the one obtained for [staurosporine]=1µM (γ = 0.72+0.18
−0.10).
This difference emphasises the strong dependence of cell death rate with the apoptotic agent.
Using now also the values for β, we fit the solution to the experimental curve for ca in the 17V
and 17VIII cell line populations to find both δ17V = 0 and δ17V III = 0. These results are plotted
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in Fig. 5(b) and Fig. 6(b).
As anticipated by E. Vourvouhaki et al. [6], this case illustrates resistance to apoptosis,
primarily upstream (β 6= 0) and possibly also downstream (δ 6= 0), dependent on the concen-
tration of staurosporine. This is supported by the observed dependence of the apoptosis time
scale on the concentration of the apoptotic agent. A higher concentration of staurosporine
increases the probability of interaction with a viable cell, as encapsulated in the larger value of
α, α(1µM) = 0.20 > α(0.1µM) = 0.15. The probability of survival is further reduced by the ob-
served decrease of upstream resistance to apoptosis with a higher concentration of staurosporine,
which can be accounted for by the smaller value of β, β17V (1µM) = 0.18 < β17V (0.1µM) = 0.19 and
β17V III(1µM) = 0.24 < β17V III(0.1µM) = 0.35. The observed higher dying rate of apoptotic cells,
on the other hand, can be accounted for by the larger decay rate γ(1µM) = 0.72 > γ(0.1µM) = 0.20.
The dependence of β and γ with the concentration of the apoptotic agent was, however, not
expected in the phenomenological framework of the kinetical model.
C. TNFα treatment in FDC-P1 cells
Here we analyse apoptosis induction by treatment with TNFα (40ng/ml=0.78µM). Similarly
to the previous case discussed, the apoptotic mechanism is that of addition of an apoptotic
agent, which is described by the system of equations (4–6), with β having the interpretation of
OS-9 overexpression modulation in apoptosis resistance. The experimental results are collected
in Figs. 6B and 6C of Ref. [6], which we reproduce in Figs. 7(a) and 8(a) respectively.
We want to solve for cv(t), given by Eqn. (4), and fit it to Fig. 7(a). Setting β = 0, we fit the
solution to the experimental curve for cv in the negative control population cell and find α =
0.32+0.01
−0.01. Given α, we consider the case where β 6= 0. Fitting the solution to the experimental
curve for cv in the OS-9-overexpressed cell line populations, we find β17V = 0.46
+0.04
−0.04 and
β17V III = 0.54
+0.03
−0.03. The resulting plots are shown in Fig. 7(b).
We then proceed to solve for ca(t), given by Eqn. (5), and to fit it to Fig. 8(a). Using the
values for α and β determined above, we fit the solution to the experimental curves for ca in
the negative control cell population and in the OS-9-overexpressed cell line populations, finding
respectively γ = 0.045+0.016
−0.016 and both δ17V = 0 and δ17V III = 0. The resulting plots are shown
in Fig. 8(b).
From the parameter estimation we conclude that this case illustrates upstream resistance to
apoptosis (β 6= 0), in agreement with what was anticipated by E. Vourvouhaki et al. [6].
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IV. DISCUSSION
In this paper we present a simple theoretical model to assess the possible effects of
OS-9 overexpression upon induction of apoptosis. We formulated a mechanistic model for
the reaction of OS-9-overexpressed cell populations to induction of apoptosis by different
mechanisms and estimated the parameters of the model from the data set available on the
possible implication of OS-9 in promotion of cell viability and resistance to apoptosis. We
summarize the results in Table I.
α β17V β17V III γ δ17V δ17V III
IL-3 0.057+0.001
−0.001 0.17
+0.04
−0.05 0.31
+0.03
−0.04 0.30
+0.04
−0.04 0.099
+0.16
−0.099 0.086
+0.14
−0.086
staurosporine 1µM 0.20+0.005
−0.01 0.18
+0.005
−0.05 0.24
+0.03
−0.07 0.72
+0.18
−0.10 0.19
+0.17
−0.16 0.27
+0.16
−0.13
staurosporine 0.1µM 0.15+0.01
−0.005 0.19
+0.06
−0.05 0.35
+0.05
−0.06 0.20
+0.005
−0.01 0 0
TNFα 0.32+0.01
−0.01 0.46
+0.04
−0.04 0.54
+0.03
−0.03 0.045
+0.016
−0.016 0 0
TABLE I: Kinetical model parameters estimated for both cell line populations.
From this Table we observe that the OS-9 overexpression-dependent parameters take non-
vanishing values. Moreover, comparing the β values across all the apoptotic inducing mecha-
nisms, we observe a strong dependence with the level of OS-9 overexpression in the two cell
line populations 17V and 17VIII. These observations suggest that OS-9 has a possible role
as an anti-apoptotic factor and that this role is dose-dependent, with the cell line population
17VIII exhibiting a greater effect in both promoting cell viability and resisting to induction of
apoptosis than 17V.
A closer look at the δ values reveals that they are very close to zero except for one situation,
namely [staurosporine] = 1µM for the 17VIII cell line population. We are persuaded to specu-
late that the OS-9 overexpression does not have a significant effect on downstream modulation
of apoptosis. The vanishing values found for the parameter δ whenever presented without error
bars are strictly vanishing, i.e. in the parameter interval [0, 1] the minimum of the cost function
is at δ = 0. In the cases where the induced average value for δ is non-vanishing, the induced
error bars can still contemplate a vanishing δ. A possible way of testing this effect would be to
measure the OS-9 overexpression in the apoptotic phase only, as described by Eqn. (3). The
number of apoptotic cells would be controlled, so that the conversion rate will only depend on
γ and δ.
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We observe that our model reflects the tendency observed in the data collected in Ref. [6]
and supports the interpretation therein advanced. There is quantitative evidence that OS-9 has
a role in the regulation of the conversion rates for cv → ca and ca → cn, as illustrated by the
non-vanishing values found for the OS-9-dependent parameters. Such evidence, however, is not
determinant since the values are small and the errors are large (ranging from around 10-100%
of the values estimated from the average data values). The results show that OS-9 contributes
primarily to promotion of viability and upstream resistance to apoptosis, as reflected by β 6= 0,
with little or no effect on downstream resistance, as reflected by the close to vanishing values for
δ. Furthermore, this function does not appear to be related to an increase in cell proliferation,
as DNA content analysis shows that cells overexpressing OS9 do not have a greater proportion
of dividing cells than control populations [6].
Some results, however, remain to be fully explained. We collapsed in the parameter α all the
intricacies of the intra-cellular, molecular processes involved in apoptosis induction and whose
relation with OS-9 we had no data to constrain or infer. TNFα gives us the highest rate of
apoptosis induction among the various other factors, followed by [staurosporine]= 1µM and
[staurosporine]= 0.1µM. The withdrawal of IL-3, being a factor that promotes cell viability, can
be seen indirectly to affect cell viability. Of the three apoptosis induction mechanisms described
in the available data sets, only the staurosporine-mediated one allowed to discriminate the effect
of the concentration of the apoptotic agent, [aa]. For that data set we observe a dependence of
α with [aa]. However, our model cannot predict the functional form of this dependence so as to
reproduce the value A = 0.125+0.003
−0.005 in the empirical expression
α(1µM)
α(0.1µM)
=
(
1
0.1
)A
(11)
relating the ten-fold increase of [aa] with α. Moreover, we observe a dependence of both β and
γ with [aa] which is not a priori encompassed by the kinetical model, since these parameters
measure the rate of cellular processes whose developement has, to our current understanding,
no relation to the environmental conditions that triggered the preceding process. We also note
that both β and γ act towards a decrease of ca, though in different ways. We venture that these
observations might be evidence of the limits of the descriptive power of the kinetical model
in face of the complexity of the biological system that it was conceived to describe as a first-
order model. The binding rates αup(i) and αdown(i) in the chemical model conceal intermediate
phenomena at levels of interaction unaccounted for by the kinetical model. We believe that a
higher-order model would be able to expose the sources of these observations, as well as allow
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for possible dependencies with the apoptotic agent or the apoptosis inducing mechanism.
Additional data from various experimental setups and from complementary measurements
are, therefore, required to unambiguously determine the function of OS-9 in cell fate and in
tumour growth, and test the model as a realistic theoretical description of the biological system.
In particular, further experiments should attempt to identify the signalling pathway through
which OS-9 exerts its function. Biochemical assays and western blot analysis will provide the
means for the identification of the proteins that OS-9 binds to in order to transmit its potential
signals. It is also essential that the function of OS-9 should be tested in in vivo models. The
establishment of knockout mice is also important in order to assess the functional importance
of OS-9 during development. Only then can we rely on the values for the parameters estimated
by the mathematical technique developed in this paper.
Addition of an apoptotic agent or withdrawal of a vital agent are expected to induce apop-
tosis through different pathways, respectively by a caspase-initiated cascade [8, 9, 10] or by
the mitochondria/cytochrome c pathway [7]. We note, however, that we cannot compare the
concentrations of different reagents/proteins since each one of them acts in a different way in
the cells. Different molecular processes entailing different cellular mechanisms can nevertheless
reflect the same populational effect, thus rendering themselves to be described by the same
mathematical model. Though at the level of description of our first-order model the parame-
ters estimated for each mechanism are not comparable, they are nonetheless valid to suggest a
contribution of OS-9 to cell viability and resistance to apoptosis.
The process of explaining a mechanism involves an active process of simplification: it is nec-
essary to make assumptions to define the most relevant components contributing to the overall
observed dynamics, while removing factors which contribute less. The isolation and identifica-
tion of the core principles governing the dynamics is paramount to the detailed understanding
of any system. [For a discussion, see Ref. [14]]. Following this approach, we present a minimal
model which is capable of capturing the structure of the experimental data. This model does
not fit perfectly the experimental data but it is built upon biologically plausible and consistent
assumptions. The values for all the parameters in the model are calculated using the least mean
square method and are, in that sense, optimal. More complex models could be derived which,
by using more parameters, would provide a better fit to the data. However, such models would
be less informative since the functional role of the additional parameters would be speculative.
Moreover, experimental data are always noisy and a perfect fit to a specific data set means loss
in generality. It is important to emphasise that very little is known about the dynamics asso-
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ciated with OS-9. Our minimal model conciliates the scarce information available with robust
assumptions to produce a simple but general model capable of quantifying the contribution of
OS-9 as a potent anti-apoptotic factor. This is a first-order model which serves as a valuable
starting point for experiments aiming at a more detailed understanding of the role of OS-9. To
the best of our knowledge, this is the only available model for the quantification of the OS-9
contribution to apoptosis.
This model can be applied to other cellular systems since it allows for the discrimination
of effects at different stages in a complex chemical mechanism and can easily be upgraded in
accordance to the functional information available.
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V. CAPTIONS
Figures denoted by (a) reproduce the data reported in Ref. [6], the points depicted giving
the readings for the different cell populations as follows: HA-expressed cell population (black),
17V cell line (dark gray), 17VIII cell line (light gray). Figures denoted by (b) show the
solutions for either cv(t) or ca(t).
Fig. 1: Number of viable cells after withdrawal of IL-3, in the presence and in
the absence of OS-9, from FACS analysis. In (a) we reproduce the data from Fig. 2B in
Ref. [6]. In (b) we show the solutions for cv(t) with α = 0.057. The black curve depicts cv(t)
when β = 0; the gray curves depict cv(t), with the dark gray curve for β17V = 0.17 and the light
grey curve for β17V III = 0.31. (The upper dashed curves represent the fittings to the maxima
data with α = 0.056, β17V = 0.19 and β17V III = 0.32; the lower dashed curves represent the
fittings to the minima data with α0 = 0.058, β17V = 0.15 and β17V III = 0.30.)
Fig. 2 Number of apoptotic cells after withdrawal of IL-3, in the presence and in
the absence of OS-9, from FACS analysis. In (a) we reproduce the data from Fig. 2C
in Ref. [6]. In (b) we show the solutions for ca(t) with α = 0.057 and γ = 0.30. The black
curve depicts ca(t) when β, δ = 0; the gray curves depict ca(t), with the dark gray curve for
β17V = 0.17 and δ17V = 0.099, and the light gray curve for β17V III = 0.31 and δ17V III = 0.086.
(The upper dashed curves represent the fittings to the maxima data with α = 0.058, γ = 0.26,
β17V = 0.15 and δ17V = 0.070, and β17V III = 0.30 and δ17V III = 0.029; the lower dashed curves
represent the fittings to the minima data with α = 0.056, γ = 0.34, β17V = 0.19 and δ17V = 0.14,
and β17V III = 0.32 and δ17V III = 0.16.)
Fig. 3 Number of viable cells after treatment with staurosporine 1µM, in the pres-
ence and in the absence of OS9, from FACS analysis. In (a) we reproduce the data from
Fig. 5B in Ref. [6]. In (b) we show the solutions for cv(t) with α = 0.20. The black curve depicts
cv(t) when β = 0. The gray curves depict cv(t), with the dark gray curve for β17V = 0.18 and
the light gray curve for β17V III = 0.24. (The upper dashed curves represent the fittings to the
maxima data with α = 0.19, β17V = 0.14 and β17V III = 0.23; the lower dashed curves represent
the fittings to the minima data with α = 0.20, β17V = 0.17 and β17V III = 0.20.)
Fig. 4 Number of apoptotic cells after treatment with staurosporine 1µM, in the
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presence and in the absence of OS-9, from FACS analysis. In (a) we reproduce the data
from Fig. 5C in Ref. [6]. In (b) we show the solutions for ca(t) with α = 0.20 and γ = 0.72. The
black curve depicts ca(t) when β, δ = 0; the gray curves depict ca(t), with the dark gray curve
for β17V = 0.18 and δ17V = 0.19, and the light gray curve for β17V III = 0.24 and δ17V III = 0.27.
(The upper dashed curves represent the fittings to the maxima data with α = 0.20, γ = 0.62,
β17V = 0.17 and δ17V = 0.09, and β17V III = 0.20 and δ17V III = 0.20; the lower dashed curves
represent the fittings to the minima data with α = 0.19, γ = 0.90, β17V = 0.14 and δ17V = 0.33,
and β17V III = 0.23 and δ17V III = 0.39.)
Fig. 5 Number of viable cells after treatment with staurosporine 0.1µM, in the
presence and in the absence of OS9, from FACS analysis. In (a) we reproduce the
data from Fig. 5B in Ref. [6]. In (b) we show the solutions for cv(t) with α = 0.15. The black
curve depicts cv(t) when β = 0; the gray curves depict cv(t), with the dark gray curve giving
β17V = 0.19 and the light gray curve β17V III = 0.35. (The upper dashed curves represent the
fittings to the maxima data with α = 0.15, β17V = 0.18 and β17V III = 0.35; the lower dashed
curves represent the fittings to the minima data with α = 0.16, β17V = 0.20 and β17V III = 0.34.)
Fig. 6 Number of apoptotic cells after treatment with staurosporine 0.1µM, in the
presence and in the absence of OS-9, from FACS analysis. In (a) we reproduce the
data from Fig. 5C in Ref. [6]. In (b) we show the solutions for ca(t) with α = 0.15 and γ = 0.20.
The black curve depicts ca(t) when β, δ = 0; the gray curves depict ca(t), with β17V = 0.19
and δ17V = 0 for the dark gray curve, with β17V III = 0.35 and δ17V III = 0 for the light gray
curve. (The upper dashed curves represent the fittings to the maxima data with α = 0.16,
γ = 0.19, β17V = 0.20 and δ17V = 0, and β17V III = 0.34 and δ17V III = 0; the lower dashed
curves represent the fittings to the minima data with α = 0.15, γ = 0.20, β17V = 0.18 and
δ17V = 0, and β17V III = 0.35 and δ17V III = 0.)
Fig. 7 Number of viable cells after treatment with TNFα, in the presence and in
the absence of OS-9, from the FACS analysis. In (a) we reproduce the data from Fig. 6B
in Ref. [6]. In (b) we show the solutions for cv(t) with α = 0.32. The black curve depicts cv(t)
when β = 0; the gray curves depict cv(t), with the dark gray curve for β17V = 0.46 and the light
grey curve for β17V III = 0.54. (The upper dashed curves represent the fittings to the maxima
data with α0 = 0.31, β17V = 0.47 and β17V III = 0.54; the lower dashed curves represent the
fittings to the minima data with α0 = 0.33, β17V = 0.46 and β17V III = 0.54.)
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Fig. 8 Number of apoptotic cells after treatment with TNFα, in the presence and
in the absence of OS-9, from the FACS analysis. In (a) we reproduce the data from
Fig. 6C in Ref. [6]. In (b) we show the solutions for ca(t) with α = 0.32 and γ = 0.045.
The black curve depicts ca(t) when β, δ = 0; the gray curves depict ca(t), with the dark
gray curve for β17V = 0.46 and δ17V = 0, and the light gray curve for β17V III = 0.54 and
δ17V III = 0. (The upper dashed curves represent the fittings to the maxima data with α = 0.33,
γ = 0.036, β17V = 0.46 and δ17V = 0, and β17V III = 0.54 and δ17V III = 0; the lower dashed
curves represent the fittings to the minima data with α = 0.31, γ = 0.055, β17V = 0.47 and
δ17V = 0.33, and β17V III = 0.54 and δ17V III = 0.)
Table I: Kinetical model parameters estimated for both cell line populations. We
summarize the values of the parameters estimated for both cell line populations and for the
three different mechanisms of apoptosis induction.
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VI. FIGURES
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FIG. 1: Number of viable cells after withdrawal of IL-3, in the presence and in the
absence of OS-9, from FACS analysis.
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FIG. 2: Number of apoptotic cells after withdrawal of IL-3, in the presence and in the
absence of OS-9, from FACS analysis.
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FIG. 3: Number of viable cells after treatment with staurosporine 1µM, in the presence
and in the absence of OS9, from FACS analysis.
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FIG. 4: Number of apoptotic cells after treatment with staurosporine 1µM, in the presence
and in the absence of OS-9, from FACS analysis.
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FIG. 5: Number of viable cells after treatment with staurosporine 0.1µM, in the presence
and in the absence of OS9, from FACS analysis.
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FIG. 6: Number of apoptotic cells after treatment with staurosporine 0.1µM, in the
presence and in the absence of OS-9, from FACS analysis.
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FIG. 7: Number of viable cells after treatment with TNFα, in the presence and in the
absence of OS-9, from the FACS analysis.
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FIG. 8: Number of apoptotic cells after treatment with TNFα, in the presence and in
the absence of OS-9, from the FACS analysis.
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